Xponance Inc. Buys 224 Shares of AstraZeneca PLC (NASDAQ:AZN)

Xponance Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.9% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 3,465 shares of the company’s stock after acquiring an additional 224 shares during the quarter. Xponance Inc.’s holdings in AstraZeneca were worth $255,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Confluence Investment Management LLC acquired a new position in shares of AstraZeneca during the 1st quarter worth $27,000. FNY Investment Advisers LLC acquired a new position in AstraZeneca in the 1st quarter worth about $29,000. Banque Transatlantique SA acquired a new position in AstraZeneca in the 4th quarter worth about $26,000. Highline Wealth Partners LLC increased its holdings in AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock worth $31,000 after purchasing an additional 340 shares in the last quarter. Finally, Mascagni Wealth Management Inc. acquired a new position in AstraZeneca in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.7%

Shares of NASDAQ:AZN opened at $68.79 on Friday. The firm has a market cap of $213.34 billion, a P/E ratio of 27.63, a PEG ratio of 1.26 and a beta of 0.37. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The business’s 50 day simple moving average is $70.78 and its two-hundred day simple moving average is $70.96. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.06 earnings per share. As a group, research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. BNP Paribas assumed coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price for the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of $89.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.